The Impact of the induction of multidrug resistance transporters in therapies by used drugs: Recent studies

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 11, 2012, Pages 1127-1134

  Hilgeroth, A ^a   Hemmer, M ^a   Coburger, C ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Drug therapy; Efflux pumps; MDR modulators; Multidrug resistance; Transporter induction studies; Transporter substrates

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C1; ABC TRANSPORTER INHIBITOR; ANTINEOPLASTIC AGENT; ATAZANAVIR; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CYCLOSPORIN A; CYTOCHROME P450; DELAVIRDINE; DEXAMETHASONE; DIGOXIN; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OMEPRAZOLE; PREGNANE X RECEPTOR; PROTEIN INHIBITOR; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; SR 12813; TIPRANAVIR; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERLUKAST;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; CANCER RESISTANCE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; NEOPLASMS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84867025073     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712802762130     Document Type: Review

References (59)

1. Gottesman, M.M.; Ling, V. The molecular basis of multidrug resistance in cancer: The early years of P-glycoprotein research. FEBS Letters, 2006, 580, 998-1009.
2. Lage, H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol. Life Science, 2008, 65, 3145-3167.
3. Pomerantz, R.J. Reservoirs, Sanctuaries, and Residual Disease: The Hiding Spots of HIV-1. HIV Clin. Trials, 2003, 4, 137-143.
4. Coburger, C.; Lage, H.; Molnár, J.; Langner, A.; Hilgeroth, A. MDR reversal properties and cytotoxic evaluation of representatives of a novel class of HIV-1 protease inhibitors. J. Pharm. Pharmacol., 2010, 62, 1704-1710.
5. Huang, Y.; Sadee, W. Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett., 2006, 239, 168-182.
6. Choi, C.H. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int., 2005, 5, 30-42.
7. Eckford, P.D.; Sharom, F.J. ABC multidrug transporters: structure, function and the role in chemoresistance. Pharmacogenomics 2008, 9, 105-127.
8. Dean, M.; Rzhetsky, A.; Allikments, R. The human ATP-binding cassette (ABC) transporter superfamily. Genom Res., 2009, 11, 1156-1166.
9. Mahon, F.X.; Belloc, F., Lagarde, V.; Chollet, C.; Moreau Gaudry, F.; Reiffers, J.; Goldman, J.M.; Melo, J.V. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood, 2003, 101, 2368-2373.
10. Matsui, H.; Takeshita, A.; Naito, K.; Shinjo, K.; Shigeno, K.; Maekawa, M.; Yamakawa, Y.; Tanimoto, M.; Kobayashi, M.; Ohnishi, K.; Ohno, R. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia, 2002, 16, 813-819.
11. Bonavida, B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene, 2007, 26, 3629-3636.
12. Coburger, C.; Wollmann, J.; Krug, M.; Baumert C., Seifert, M.; Molnár, J.; Lage, H.; Hilgeroth, A. Novel structure-activity relationships and selectivity profiling of cage dimeric 1,4- dihydropyridines as multidrug resistance (MDR) modulators. Bioorg. Med. Chem., 2010, 18, 4983-4990.
13. Sharom, F.J. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics, 2008, 9, 105-127.
14. Livingston, D.M.; Silver, D.P. Crossing over to drug resistance. Nature, 2008, 451, 1066-1067.
15. Rees, D.C.; Johnson, E.; Lewinson, O. ABC transporter: the power to change. Nat. Rev. Mol. Cell Biol., 2009, 10, 218-227.
16. Dean, M.; Annilo, T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu. Rev. Genomics Human Genet., 2005, 6, 123-142.
17. Bakos, E.; Homolya, L. Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). Pflugers Arch., 2007, 453, 621-641.
18. Avendanó, C.; Menéndez, J.C. Recent Advances in Multidrug Resistance Modulators. Med. Chem. Rev.-Online, 2004, 1, 414-444.
19. Baumert, C.; Hilgeroth, A. Recent Advances in the Development of P-gp Inhibitors. Anticancer Agents Med. Chem., 2009, 9, 415-436.
20. Tan, B.; Piwnica-Worms, D.; Ratner, L. Multidrug resistance transporters and modulation. Curr. Opin. Oncol., 2000, 12, 450-458.
21. Leschziner, G.D.; Andrew, T.; Pirmohamed, M.; Johnson, M.R. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J., 2007, 7, 154-179.
22. Tain, Q.; Zhang, J.; Chan, E.; Duan, W.; Zhou, S. Multidrug resistance proteins (MRPs) and implication in drug development. Drug Development Res., 2005, 64, 1-18.
23. Gillet, J.P.; Efferth, T.; Remacle, J. Chemotherapy-induced resistance by ATP binding cassette transporter genes. Biochim. Biophys. Acta, 2007, 1775, 237-262.
24. Kelly, R.J.; Draper, D.; Chen, C.C. A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer. Clin. Cancer Res., 2011, 17, 569-580.
25. Harmsen, S.; Meijerman, I.; Febus, C.L.; Maas-Bakker, R.F.; Beijnen, J.H.; Schellens, J.H. PXR-mediated induction of Pglycoprotein by anticancer drugs in a human colon adenocarcinomaderived cell line. Cancer Chemother. Pharmacol., 2009, 66, 765-771.
26. Shitl, A.A. Signal transduction pathways and transcriptional mechanisms as targets for prevention of emergence of multidrug resistance in human cancer cells. Curr. Drug Tragets, 2001, 2, 57-77.
27. Coburger, C.; Lage, H.; Molnár, J.; Hilgeroth, A. Impact of Novel MDR Modulators on Human Cancer Cells: Reversal Activities and Induction Studies. Pharm. Res., 2009, 26, 182-188.
28. Luqmani, Y.A. Mechanisms of Drug Resistance in Cancer Chemotherapy. Med. Princ. Pract., 2005, 14 (Suppl.1), 35-48.
29. Scotto, K.W. Transcriptional regulation of ABC drug transporters. Oncogene, 2003, 22, 7496-7511.
30. Kim, R.B.; Fromm, M.F.; Wandel, C.; Leake, B.; Wood, A.J.J.; Roden, D.M.; Wilkinson, B.R. The drug transporter P-glycoprotein limits oral absorption and the brain entry of HIV-1 protease inhibitors. J. Clin. Invest., 1998, 101, 289-294.
31. Huisman, M.T.; Smit, J.W.; Wiltshire, H.R.; Hoetelmans, R.M.; Beijnen, J.H.; Schinkel, A.H. P-Glycoprotein limits oral availability, brain and fetal penetration of saquinavir even with high doses of ritonavir. Mol. Pharmacol., 2001, 59, 806-813.
32. Ronaldson, P.T.; Lee, G.; Dallas, Sh.; Bendayan, R. Involvement of P-Glycoprotein Transport of Saquinavir and Indinavir in Rat Brain Microvessel Endothelial and Microglia Cell Lines. Pharm. Res., 2004, 21, 811-818.
33. Drewe, J.; Gutman, H.; Fricker, G.; Torok, M.; Beglinger, C.; Huwyler, J. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem. Pharmacol., 1999, 57, 1147-1152.
34. Usansky, H.H.; Hu, P.; Sinko, P.J. Differential Roles of P- Glycoprotein, Multidrug Resistance-Associated Protein 2, and CYP3A on Saquinavir Oral Absorption in Sprague-Dawley Rats. Drug Metab. Disp., 2008, 36, 863-869.
35. Cooper, C.L.; van Heeswijk, R.P.G.; Gallicano, K.; Cameron, D.W. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin. Infect. Dis., 2003, 36, 1585-1592.
36. Youle, M. Overview of boosted protease inhibitors in treatmentexperienced patients. J. Antimicrob. Chemother., 2007, 60, 1195-1205.
37. Busse, K.H.; Penzak, S.R. Pharmacological enhancement of protease inhibitor with ritonavir: An update. Expert Rev. Clin. Pharmacol., 2008, 1, 533-545.
38. Richter, M.; Gyémant, N.; Molnár, J.; Hilgeroth, A. Comparative Effects on Intestinal Absorption in Situ by P-glycoprotein- Modifying HIV Protease Inhibitors. Pharm. Res., 2004, 21, 1862-1866.
39. Perloff, M.D.; Von Moltke, L.L.; Marchand, J.E.; Greenblatt, D.J. Ritonavir induces P-glycoprotein expression, multidrug resistanceassociated protein (MRP1) expression, and drug transportermediated activity in a human intestinal cell line. Pharm. Sci., 2001, 90, 1829-1837.
40. Perloff, M.D.; Von Moltke, L.L.; Fahey, J.M.; Greenblatt, D.J. Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. J. Pharm. Pharmacol., 2007, 59, 947-953.
41. Zastre, J.A.; Chan, G.N.Y.; Ronaldson, P.T.; Ramaswamy, M.; Couraud, P.O.; Romero, I.A.; Weksler, B.; Bendayan, M.; Bendayan, R. Up-regulation of P-glycoprotein by HIV protease Inhibitors in a Human Brain Microvessel Endothelial Cell Line. J. Neurosci. Res., 2009, 87, 1023-1036.
42. Gupta, A.; Thummel, K.E.; Unadkat, J.D. Induction of CYP3A4 and MDR1 by anti-HIV protease inhibitors in human intestinal adenocarcinoma cell line. Drug. Metab. Rev., 2006, 38, 111-112.
43. Weiss, J.; Herzog, M., König, S.; Storch, C.H.; Ketabi-Kiyanvash, N.; Haefeli, W.E. Induction of multiple drug transporters by efavirenz. J. Pharmacol. Sci., 2009, 109, 242-250.
44. Almond, L.M.; Hoggard, P.G.; Edirisinghe, D.; Khoo, S.H.; Back, D.J. Intracellular and plasma pharmacokinetics of efavirenz in HIVinfected individuals. J. Antimicrob. Chemother., 2005, 56, 738-744.
45. Weiss, J.; Weis, N.; Ketabi-Kiyanvash, N.; Storch, C.H.; Haefeli, W.E. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Eur. J. Pharmacol., 2007, 579, 104-109.
46. Mukwaya, G.; MacGregor, T.; Hoelscher, D.; Heming, Th.; Legg, D.; Kavanaugh, K.; Johnsom, Ph.; Sabo, J.P.; McCallister, S. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob. Agents, 2005, 49, 4903-4910.
47. Vourvahis, M.; Kashuba, A.D.M. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavirenhanced tipranavir. Pharmacother., 2007, 27, 888-909.
48. Solbach, T.F.; Paulus, B.; Weyand, M.; Eschenhagen, T.; Zolk, O.; Fromm, M.F. ATP-binding cassette transporters in human heart failure. Naunyn Schmiedebergs Arch. Pharmacol., 2008, 377, 231-243.
49. Weiss, J.; Sauer, A.; Herzog, M.; Böger, R.H.; Haefeli, W.E.; Benndorf, R.A. Interaction of Thiazolidinediones (Glitazones) with the ATP-Binding Cassette Transporters P-Glycoprotein and Breast Cancer Resistance Protein. Pharmacology, 2009, 84, 264-270.
50. Szatmari, I.; Vamosi, G.; Brazda, P.; Balint, B.L.; Benko, S.; Szeles, L.; Jeney V.; Ozvegy-Laczka, C.; Szanto, A.; Barta, E.; Balla, J.; Sarkadi, B.; Nagy, L. Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells. J. Biol. Chem., 2006, 281, 23812-23823.
51. Borst, P.; Elferink, R.O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem., 2002, 71, 537-592.
52. Dean, M. ABC transporters, drug resistance, and cancer stem cells. J. Mammary Gland Biol. Neoplasia, 2009, 14, 3-9.
53. Nishimura, M.; Koeda, A.; Morikawa, H.; Satoh, T.; Narimatsu, S.; Naito, S. Comparison of inducibility of multidrug resistance (MDR)1, multidrug resistance-associated protein (MRP)1, and MRP2 mRNAs by prototypical microsomal enzyme inducers in primary cultures of human and cynomolgus monkey hepatocytes. Biol. Pharm. Bull., 2008, 31, 2068-2072.
54. Sartori, S.; Trevisani, L.; Nielsen, I.; Tassinari, D.; Panzini, I.; Abbasciano, V. Randomized Trial of Omeprazole or Ranitidine Versus Placebo in the Prevention of Chemotherapy-induced Gastroduodenal Injury. J. Clin. Oncol., 2000, 18, 463-467.
55. Aszalos, A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) I. Preclinical aspects. Drug Disc. Today, 2007, 12, 833-837.
56. Hilgeroth, A.; Molnár, J.; Declercq, E. Using Molecular Symmetry to Form New Drugs: Hydroxymethyl-substituted 3,9- Diazatetraasteranes as the First Class of Symmetric MDR Modulators. Angew. Chem. Int. Ed., 2002, 114, 3772-3775.
57. Wollmann, J.; Baumert, C.; Erlenkamp, G.; Sippl, W.; Hilgeroth, A. Novel Insight into Inhibitor Binding of Highly Symmetric HIV-1 Protease. ChemBioChem, 2008, 9, 874-878.
58. Ronald, E.; Langford, D.; Eliezer, M. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nature Rev. Neurosci., 2007, 8, 33-44.
59. Krühn, A.; Wang, A.; Fruehauf, J.H.; Lage, H. Delivery of short hairpin RNAs by transkingdom RNA interference modulates the classical ABCB1-mediated multidrug-resistant phenotype of cancer cells. Cell Cycle, 2009, 20, 3349-3354.